PatentApr 22, 2026, 07:03 AM
Rafael Holdings' Cyclo Therapeutics licenses MIT patent for Alzheimer's
AI Summary
Rafael Holdings' subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (MIT) for U.S. Patent No. 12285440. This license covers the use of cyclodextrins, including Trappsol® Cyclo™, in Alzheimer's Disease patients carrying the ApoE4 genetic mutation, which is present in 50-70% of AD patients. The agreement strengthens the company's intellectual property and aims to accelerate a potential breakthrough by addressing the underlying pathology of AD through improved cholesterol transport in the brain.
Key Highlights
- Cyclo Therapeutics licensed U.S. Patent No. 12285440 from MIT.
- License covers cyclodextrin use in Alzheimer's patients with ApoE4 mutation.
- ApoE4 genetic mutation affects 50-70% of Alzheimer's patients.
- Trappsol® Cyclo™ aims to improve cholesterol transport in CNS cells.
- Preclinical data suggests reduced tau-pathology and improved memory.
Price Impact
More from RFL